Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation

Journal of Internal Medicine

Volumn 264, Issue 1, 2008, Pages 50-61

  Lip, G Y H ^a   Frison, L ^b   Grind, M ^b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Atrial fibrillation; Paroxysmal atrial fibrillation; Stroke; Warfarin; Ximelagatran

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; WARFARIN; XIMELAGATRAN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA ANALYSIS; ELDERLY CARE; EMBOLISM; FEMALE; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; STATISTICAL ANALYSIS; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; AZETIDINES; BENZYLAMINES; COHORT STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STROKE; WARFARIN;

EID: 45149118064     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2007.01909.x     Document Type: Article

References (11)

1. Levy S, Camm AJ, Saksena S et al. Working group on arrhythmias, working group on cardiac pacing of the European Society of Cardiology, North American Society of Pacing and Electrophysiology. International consensus on nomenclature and classification of atrial fibrillation; a collaborative project of the working group on arrhythmias and the working group on cardiac pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Europace 2003 5 : 119 22.
2. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994 89 : 224 7.
3. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke prevention in atrial fibrillation investigators. J Am Coll Cardiol 2000 35 : 183 7.
4. Lip GY, Boos C. Antithrombotic therapy for atrial fibrillation. Heart 2006 92 : 155 6.
5. Olsson SB. Executive Steering Committee on behalf of the SPORTIF III investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003 362 : 1691 8.
6. SPORTIF Executive Committee for the SPORTIF V Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 2005 293 : 690 8.
7. ACTIVE Writing Group on behalf of the ACTIVE Investigators. Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation Clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet 2006 367 : 1903 12.
8. Capucci A, Santini M, Padeletti L et al. Italian AT500 Registry Investigators. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 2005 15 : 46.
9. Hohnloser SH, Capucci A, Fain E et al. ASSERT Investigators and Committees. Asymptomatic atrial fibrillation and stroke evaluation in pacemaker patients and the atrial fibrillation reduction atrial pacing trial (ASSERT). Am Heart J 2006 Sep 152 : 442 7.
10. Lin HJ, Wolf PA, Benjamin EJ, Belanger AJ, D'Agostino RB. Newly diagnosed atrial fibrillation and acute stroke. The Framingham study. Stroke 1995 26 : 1527 30.
11. Oral H, Chugh A, Ozaydin M et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation. 2006 Aug 22 114 : 759 65. Epub 2006 Aug 14.